Trial Profile
Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2024
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Solasia Pharma
- 23 Jun 2022 According to a Solasia Pharma media release, based on the results of this study, the Ministry of Health, Labor and Welfare (MHLW) has approved the organoarsenic drug DARVIAS (SP-02) Injection 135mg for relapsed or refractory Peripheral T-Cell Lymphoma.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 22 Jul 2021 Status changed from active, no longer recruiting to completed.